Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital.

The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye.

Get the full story at our sister site, Drug Delivery Business News.